Mustang Bio, Inc. (MBIO)

NASDAQ: MBIO · IEX Real-Time Price · USD
0.730
-0.020 (-2.65%)
Aug 16, 2022 11:27 AM EDT - Market open
-2.65%
Market Cap 77.43M
Revenue (ttm) n/a
Net Income (ttm) -75.95M
Shares Out 106.07M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 157,081
Open 0.750
Previous Close 0.750
Day's Range 0.720 - 0.750
52-Week Range 0.510 - 3.090
Beta 1.64
Analysts Buy
Price Target 7.14 (+878.1%)
Earnings Date Aug 15, 2022

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare g... [Read more...]

Industry Biotechnology
Employees 102
Stock Exchange NASDAQ
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MBIO stock is "Buy." The 12-month stock price forecast is 7.14, which is an increase of 878.08% from the latest price.

Price Target
$7.14
(878.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Comb...

WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for t...

Multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed or refractory B-NHL and CLL under Mustang's IND now open to enrollment Multicenter Phase 1/2 clinical trial...

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of ...

94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy

Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency

Mustang Bio Inc (NASDAQ: MBIO) announced interim data from the Phase 1/2 trial of MB-107, lentiviral gene therapy for X-linked severe combined immunodeficiency (X-SCID), also known as bubble boy disease...

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vec...

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation

Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Data from two programs selected for oral presentations at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting and the European Hematology Association 2022 Hybrid Congress this quart...

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Tar...

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma

Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immuno...

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relaps...

Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those who received ...

Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

Fred Hutch's Dr. Mazyar Shadman to present data on Mustang's autologous CAR T-cell therapy for the treatment of B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia Fred Hutch's Dr. Mazyar Shad...

Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C13...

MB‐101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) are well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials

Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...

Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...

Mustang Bio to Participate in Three March 2022 Investor Conferences

WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children's Hospital Abstract A...

WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...

Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital

WORCESTER, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...

Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022...

WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards

WORCESTER, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Drug (IND) application for MB-207 in patients with X-linke...

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked...

WORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transpl...

WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

Mustang Bio Added to the NASDAQ Biotechnology Index

WORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Ho...

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process